Baseline characteristics
| Stage IVB (total, n=33) | CT only (n=10) | CRT (n=23) | P value | |
| Age (years) (median (range) | 53 (28–78) | 46 (34–76) | 57 (28–78) | 0.4 |
| Performance status (n (%)) | ||||
| ECOG 0 | 23 (70) | 7 (70) | 16 (70) | >0.9 |
| ECOG 1 | 10 (30) | 3 (30) | 7 (30) | |
| Symptoms at diagnosis (n (%)) | ||||
| PCB/PMB | 24 (73) | 4 (40) | 20 (87) | 0.01 |
| Other | 9 (27) | 6 (60) | 3 (13) | |
| Histology (n (%)) | ||||
| Adenocarcinoma | 8 (24) | 3 (30) | 5 (22) | 0.7 |
| Squamous cell carcinoma | 22 (67) | 7 (70) | 15 (65) | |
| Other | 3 (9.1) | 0 (0) | 3 (13) | |
| Grade (n (%)) | ||||
| Well differentiated | 4 (12) | 0 (0) | 4 (17) | 0.2 |
| Moderately differentiated | 7 (21) | 1 (10) | 6 (26) | |
| Poorly differentiated | 22 (67) | 9 (90) | 13 (57) | |
| PD-L1 CPS status (n (%)) | ||||
| ≥1% | 7 (21) | 2 (20) | 5 (22) | 0.001 |
| <1% | 7 (21) | 6 (60) | 1 (4) | |
| Unknown | 19 (58) | 2 (20) | 17 (74) | |
| Para-aortic lymph nodes (n (%)) | ||||
| No | 12 (36) | 2 (20) | 10 (43) | 0.3 |
| Yes | 21 (64) | 8 (80) | 13 (57) | |
| Pelvic lymph nodes (n (%)) | ||||
| No | 3 (9) | 0 (0) | 3 (13) | 0.5 |
| Yes | 30 (91) | 10 (100) | 20 (87) | |
| Pattern of metastasis (n (%)) | ||||
| Hematogenous spread | 19 (58) | 6 (60) | 13 (57) | >0.9 |
| Lymphatic spread | 14 (42) | 4 (40) | 10 (43) | |
| Oligometastatic vs polymetastatic (n (%)) | ||||
| Oligometastatic disease | 25 (76) | 3 (30) | 22 (96) | <0.001 |
| Polymetastatic disease | 8 (24) | 7 (70) | 1 (4) | |
| Systemic treatment with CRT (n (%)) | ||||
| Adjuvant | 5 (15) | NA | 5 (22) | 0.028 |
| Neoadjuvant | 6 (18) | NA | 6 (26) | |
| No | 22 (67) | NA | 12 (52) | |
| Brachytherapy (n (%)) | ||||
| Yes | 20 (61) | NA | 20 (87) | <0.001 |
| No | 13 (39) | NA | 3 (13) | |
| Duration of RT treatment (median (range)) (days) | 59 (18–93) | NA | 59 (18–93) | |
| Time to completion of RT (n (%)) | ||||
| <8 weeks | 9 (39) | NA | 9 (39) | >0.9 |
| ≥8 weeks | 14 (61) | NA | 14 (61) | |
| Recurrence (n (%)) | ||||
| Yes | 27 (82) | 10 (100) | 17 (74) | 0.14 |
| No | 6 (18) | 0 (0) | 6 (26) | |
| Pattern of failure (n (%)) | ||||
| No recurrence | 6 (18) | 0 (0) | 6 (26) | 0.3 |
| Distant recurrence | 20 (61) | 10 (100) | 10 (43) | |
| Regional recurrence | 3 (9) | NA | 3 (13) | |
| In-field recurrence | 4 (12) | NA | 4 (18) | |
| Best response after CRT (n (%)) | ||||
| CR | 14 (43) | 2 (20) | 12 (52) | 0.03 |
| PR | 9 (27) | 6 (60) | 3 (13) | |
| PD | 10 (30) | 2 (20) | 8 (35) | |
| Death (n (%)) | ||||
| Death related to cervical cancer | 19 (58) | 8 (80) | 11 (48) | 0.13 |
CPS, combined pathology score; CR, complete response; CRT, chemoradiation; CT, chemotherapy; ECOG, Eastern Cooperative Oncology Group; NA, not applicable; PCB, post-coital bleeding; PD, progressive disease; PD-L1, programmed death ligand 1; PMB, post-menopausal bleeding; PR, partial response; RT, radiation therapy.